Indian Economy News

DocsApp raises US$ 9.5 million in Series B funding

DocsApp has raised US$ 9.5 million in Series B funding, led by Bessemer Venture Partners India, Fusian Capital, Rebright Partners and Milliways Fund LLC. The digital healthcare platform plans to utilise these funds to enhance its doctor base, patient reach and develop its product to move a step closer to its aim of providing quality healthcare to all.

Patients can talk to a doctor over voice or video call in their mother tongue with the help of technology. Currently, DocsApp provides consultations in all Indian languages. The app has served to more than two crore Indians since its launch. More than 10,000 doctors are registered with DocsApp to help patients across the country. Over the last year, DocsApp has delivered medicines to more than 2 lakh Indians in a safe and secure manner and done 1 lakh home pickup of samples for lab tests.

“The outlook that we as a team share is that, with technology by our side we are able to provide quality healthcare access to millions of people. What motivates us is the direct impact that we create in making our customers’ lives healthy and happy. To overcome the current challenging times, we will continue to help more patients across the country. We are working towards making consults easier for our customers by providing services in the most remote areas of our country” said Mr Satish Kannan, CEO and Co-founder, DocsApp.

In order to fight with COVID-19 situation, DocsApp has integrated a special feature, in the form of an exclusive medical department dedicated to Coronavirus, where consultation is provided free of cost. This initiative has, so far, prompted 40K queries from all over the country. It has also partnered with different accredited labs to provide COVID-19 lab test for residents in Delhi, Mumbai, Pune, Karnataka, Haryana, Gujarat and Tamil Nadu. A Coronavirus Risk Assessment Tool was also launched to help individuals assess the level of possibility of them being affected. This innovative tool, based on simple inter-active questions, generates a risk score based on an individual’s symptoms.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.